Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167)
:1167
Want to see HK:1167 full AI Analyst Report?
1167 Stock Chart & Stats
HK$8.06
HK$0.04(3.17%)
At close: 4:00 PM EST
HK$8.06
HK$0.04(3.17%)
Day’s Range― - ―
52-Week RangeHK$4.19 - HK$11.80
Previous CloseN/A
Volume546.60K
Average Volume (3M)7.94M
Market Cap
HK$4.20B
Enterprise ValueHK$3.37B
Total Cash (Recent Filing)HK$1.13B
Total Debt (Recent Filing)HK$165.24M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 28, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding791,755,070
10 Day Avg. Volume5,388,349
30 Day Avg. Volume7,936,853
Financial Highlights & Ratios
PEG Ratio3.12
Price to Book (P/B)5.75
Price to Sales (P/S)84.99
P/FCF Ratio-23.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.00Price Target Upside36.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.4
Revenue Forecast (FY)HK$723.51M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageLow debt relative to equity gives Jacobio structural financial flexibility to fund ongoing R&D and milestone-driven programs without immediate heavy interest burdens. For a clinical-stage biotech, manageable leverage lowers near-term refinancing pressure and preserves optionality for partnerships or selective capital raises over months.
Partner-driven Business ModelA collaboration/licensing model provides durable, non-operating contingent cash levers—upfront and milestone payments and royalties—that can materially extend runway when clinical or regulatory milestones are met. Reliance on partner economics diversifies funding sources and aligns R&D spend with external commercialization capabilities.
Focused R&D FranchiseA clear, focused strategy on small-molecule targeted oncology therapies concentrates scientific expertise and development resources. This specialization supports efficient trial design, partner interest, and potential accelerated value capture if lead candidates meet endpoints, sustaining strategic appeal to collaborators over the medium term.
Bears Say
Severe Revenue DeclineA c.74% year-over-year revenue drop is a material structural setback for a clinical-stage firm that relies on partner payments and milestone timing. Sustained top-line weakness undermines internal funding capacity, raises dependency on external capital, and materially increases execution risk for ongoing programs over the next several quarters.
Weak Cash GenerationPersistent negative operating and free cash flow, with rising 2025 cash burn, creates structural funding sensitivity for a company without product revenues. This elevates the probability of near-term financing, partnership-dependent milestones, or equity dilution, constraining strategic choices and increasing execution risk across the pipeline.
Cumulative Losses And Value DilutionDeclining equity and persistently negative ROE reflect cumulative losses and potential shareholder dilution from prior financing. Over time, this erodes balance-sheet resilience, limits the firm's ability to self-fund development, and may force dilutive raises or unfavorable deal terms that reduce long-term shareholder value if profitability isn't achieved.
Jacobio Pharmaceuticals Group Co., Ltd. News
1167 FAQ
What was Jacobio Pharmaceuticals Group Co., Ltd.’s price range in the past 12 months?
Jacobio Pharmaceuticals Group Co., Ltd. lowest stock price was HK$4.19 and its highest was HK$11.80 in the past 12 months.
What is Jacobio Pharmaceuticals Group Co., Ltd.’s market cap?
Jacobio Pharmaceuticals Group Co., Ltd.’s market cap is HK$4.20B.
When is Jacobio Pharmaceuticals Group Co., Ltd.’s upcoming earnings report date?
Jacobio Pharmaceuticals Group Co., Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 98 days.
How were Jacobio Pharmaceuticals Group Co., Ltd.’s earnings last quarter?
Jacobio Pharmaceuticals Group Co., Ltd. released its earnings results on Mar 09, 2026. The company reported -HK$0.126 earnings per share for the quarter, missing the consensus estimate of -HK$0.011 by -HK$0.115.
Is Jacobio Pharmaceuticals Group Co., Ltd. overvalued?
According to Wall Street analysts Jacobio Pharmaceuticals Group Co., Ltd.’s price is currently Undervalued.
Does Jacobio Pharmaceuticals Group Co., Ltd. pay dividends?
Jacobio Pharmaceuticals Group Co., Ltd. does not currently pay dividends.
What is Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate?
Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate is 0.01.
How many shares outstanding does Jacobio Pharmaceuticals Group Co., Ltd. have?
Jacobio Pharmaceuticals Group Co., Ltd. has 791,755,070 shares outstanding.
What happened to Jacobio Pharmaceuticals Group Co., Ltd.’s price movement after its last earnings report?
Jacobio Pharmaceuticals Group Co., Ltd. reported an EPS of -HK$0.126 in its last earnings report, missing expectations of -HK$0.011. Following the earnings report the stock price went down -0.325%.
Which hedge fund is a major shareholder of Jacobio Pharmaceuticals Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1167
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jacobio Pharmaceuticals Group Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$11.00 (36.41% Upside)
HK$11.00 (36.41% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
301.85%
12-Months-Change
Fundamentals
Return on Equity
-17.64%
Trailing 12-Months
Asset Growth
0.44%
Trailing 12-Months
Company Description
Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.
1167 Stock 12 Month Forecast
Average Price Target
HK$11.00
▲(36.41% Upside)
Technical Analysis
Antengene Corporation Limited
―
Genor Biopharma Holdings Limited
―
Alphamab Oncology
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---